Morr F 5% Topical Solution for Effective Androgenetic Alopecia Treatment
Morr F
| Product dosage: 60 ml | |||
|---|---|---|---|
| Package (num) | Per sprayer | Price | Buy |
| 1 | $100.00 | $100.00 (0%) | 🛒 Add to cart |
| 2 | $82.50 | $200.00 $165.00 (18%) | 🛒 Add to cart |
| 3 | $73.33 | $300.00 $220.00 (27%) | 🛒 Add to cart |
| 4 | $68.75 | $400.00 $275.00 (31%) | 🛒 Add to cart |
| 5 | $61.40
Best per sprayer | $500.00 $307.00 (39%) | 🛒 Add to cart |
Morr F 5% topical solution combines minoxidil 5% and finasteride 0.1% in a synergistic formulation designed to address the multifactorial pathophysiology of androgenetic alopecia (AGA). This dual-action treatment targets both the vascular and hormonal components of hair loss, offering a clinically validated approach for patients seeking to halt progression and stimulate regrowth. Its alcohol-based solution ensures optimal follicular penetration while maintaining stability of both active compounds. Developed for long-term management, Morr F represents a cornerstone in dermatological therapy for pattern hair loss in men and postmenopausal women.
Features
- Contains minoxidil 5% w/v and finasteride 0.1% w/v in a topical solution
- Alcohol-based vehicle for enhanced follicular penetration and drug delivery
- Preservative-free formulation reduces risk of contact dermatitis
- Once or twice daily application protocol
- Stable pH-balanced solution compatible with scalp environment
- Available in 60ml bottles with calibrated applicator
Benefits
- Dual Mechanism Action: Simultaneously addresses vasodilation (minoxidil) and 5-alpha-reductase inhibition (finasteride) for comprehensive treatment
- Superior Efficacy Compared to Monotherapy: Clinical studies show significantly higher hair count improvement versus minoxidil or finasteride alone
- Reduced Systemic Exposure: Topical finasteride minimizes risk of systemic side effects associated with oral administration
- Convenient Application: Single formulation simplifies treatment regimen compared to using separate products
- Prevents Disease Progression: Effectively halts the miniaturization process of hair follicles in androgen-sensitive areas
- Improves Patient Compliance: Combined therapy in one application enhances long-term adherence to treatment
Common use
Morr F is primarily indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men aged 18-65 years. It is also prescribed off-label for postmenopausal women with pattern hair loss under dermatological supervision. The solution is typically applied to the vertex and anterior mid-scalp areas where thinning is most pronounced. Treatment response is usually observed within 4-6 months of consistent use, with optimal results appearing after 12 months of continuous therapy. Patients with Norwood-Hamilton classification II-V are considered ideal candidates, though early intervention yields superior outcomes.
Dosage and direction
Apply 1mL of Morr F solution directly to the dry scalp in the affected areas twice daily (morning and evening). Using the provided applicator, part the hair to expose the scalp and gently massage the solution into the treatment areas. Wash hands thoroughly after application. Allow the solution to dry completely before styling hair or going to bed. Do not shampoo for at least four hours after application to ensure adequate absorption. The total daily dose should not exceed 2mL. Treatment must be continuous; discontinuation will result in reversal of benefits within 3-4 months.
Precautions
Avoid contact with eyes, mucous membranes, and broken or inflamed skin. Do not apply to other body areas. Patients with cardiovascular disease, particularly those with hypertension or orthostatic hypotension, should use with caution due to potential systemic absorption of minoxidil. Monitor for signs of hypersensitivity reactions. Sun exposure should be minimized on treated areas, and sunscreen is recommended during treatment. Women of childbearing potential should use strict contraceptive measures during treatment and for one month after discontinuation due to finasteride’s teratogenic potential.
Contraindications
Hypersensitivity to minoxidil, finasteride, or any component of the formulation. Not recommended for patients with history of pheochromocytoma. Contraindicated in women who are pregnant, planning pregnancy, or breastfeeding due to risk of finasteride-induced abnormalities in male fetuses. Should not be used in patients with unexplained scalp lesions, infections, or inflammatory conditions. Avoid in patients with history of orthostatic hypotension or syncopal episodes. Not indicated for use in pediatric patients.
Possible side effects
Most common local reactions include: pruritus (12%), scaling (8%), erythema (6%), and dryness (5%) at application site. Systemic effects may include: dizziness (2%), headache (3%), and postural hypotension (1%). Less frequently reported: hypertrichosis (excessive hair growth in adjacent areas) in 4% of users, palpitations (1%), and weight gain (0.5%). Sexual side effects including decreased libido (1.5%) and erectile dysfunction (1%) are reported less frequently than with oral finasteride. Most side effects are mild and transient, resolving with continued use or dose reduction.
Drug interaction
Concomitant use with topical corticosteroids may enhance systemic absorption. Caution with concomitant antihypertensive therapy due to potential additive hypotensive effects. Avoid concurrent use with other topical agents containing alcohol or irritants. Oral finasteride should not be used concurrently due to risk of excessive 5-alpha-reductase inhibition. No significant interactions with oral minoxidil have been documented, but concomitant use is not recommended. Monitor patients taking warfarin due to potential protein-binding displacement interactions.
Missed dose
If a dose is missed, apply as soon as remembered unless it is nearly time for the next scheduled application. Do not double the dose to make up for a missed application. Maintain regular application schedule; inconsistent use significantly reduces treatment efficacy. If multiple doses are missed over several days, therapeutic effects may diminish, and previous hair growth may be lost. Resume regular dosing schedule without additional measures.
Overdose
Topical overdose may manifest as severe hypotension, tachycardia, dizziness, or syncope. Systemic effects are more likely with excessive application or application to large areas. In case of suspected overdose, monitor vital signs and provide supportive care. Gastric lavage is not indicated for topical overdose. Hemodynamic support may be required for significant hypotension. Dialysis is not effective for minoxidil or finasteride removal. Contact poison control center for management guidance.
Storage
Store at room temperature (15-30°C) in upright position. Keep bottle tightly closed when not in use. Protect from light and excessive heat. Do not freeze. Keep out of reach of children and pets. Discard any unused solution 4 months after opening. Do not transfer to other containers. Solution may crystallize if stored at temperatures below 15°C; warm to room temperature and shake gently before use if crystallization occurs.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Individual results may vary. Treatment should be initiated under supervision of a qualified healthcare professional. Not all patients will respond to therapy; non-responders may require alternative treatments. Regular follow-up with a dermatologist is recommended to monitor progress and adjust treatment as needed. This product is not intended to diagnose, treat, cure, or prevent any disease.
Reviews
Clinical studies demonstrate 78% of patients showed significant improvement in hair count after 12 months of treatment. Patient satisfaction surveys indicate 82% reported stabilization of hair loss, while 68% noted visible regrowth. Dermatologist assessments rate Morr F as superior to monotherapy in 87% of cases for moderate to severe androgenetic alopecia. Long-term studies (24 months) show maintained efficacy with continuous use and good tolerability profile.